Creatine and Brain Energy: What the 2026 CABA Trial Found

Emerging research suggests creatine supplementation may do more than build muscle — it may also support brain energy, memory and focus. The 2026 CABA trial, conducted at the University of Kansas Medical Center, found that daily creatine measurably increased brain phosphocreatine levels and was associated with better performance on standardized cognitive assessments in older adults. It is some of the clearest human evidence to date that oral creatine can raise the brain's energy reserves.

What Is the CABA Trial?

The CABA trial was a clinical study published in a peer-reviewed clinical journal in early 2026 by researchers at the University of Kansas Medical Center. Twenty older adults received 20 grams of creatine daily for eight weeks.

Brain phosphocreatine (PCr) levels were measured using magnetic resonance spectroscopy (MRS) — a non-invasive neuroimaging technique that quantifies phosphorus-containing metabolites in neural tissue in vivo. Cognitive function was assessed at baseline and at eight weeks using standardized instruments covering sorting tasks, reading comprehension, and sustained attention.

The study was designed to test one core hypothesis: can raising brain creatine stores via oral supplementation improve ATP availability in the aging brain?

How Creatine Affects Brain Energy Metabolism

Neurons are among the most energetically demanding cells in the body. The brain represents roughly 2% of body weight but consumes approximately 20% of total resting energy expenditure — almost entirely in the form of adenosine triphosphate (ATP).

As we age, mitochondria become less efficient at oxidative phosphorylation, the primary ATP-production pathway. That leaves less energy available for synaptic signaling, neuroplasticity, and memory consolidation.

Creatine supports brain energy through the creatine kinase–phosphocreatine (CK-PCr) system. Phosphocreatine serves as a rapid-access ATP buffer: when cellular ATP is depleted, the enzyme creatine kinase catalyzes the transfer of a phosphate group from phosphocreatine to ADP, regenerating ATP within milliseconds. This process bypasses the slower mitochondrial production pathway and sustains neuronal function during periods of high metabolic demand or impaired oxidative capacity.

What the 2026 CABA Trial Found

After eight weeks of 20g/day creatine supplementation, the CABA trial reported two primary findings confirmed by objective neuroimaging and standardized cognitive testing:

• Brain phosphocreatine increased by 10–15%, confirmed via MRS neuroimaging. This confirms that oral creatine successfully crosses the blood-brain barrier and raises intracellular creatine concentrations in neural tissue — measured directly by spectroscopy.
• Cognitive scores improved on sorting tasks, reading comprehension, and sustained attention. Participants scored measurably higher on these instruments at eight weeks compared to baseline.

The authors linked the size of the effect to how low participants' phosphocreatine levels were at baseline — suggesting people with lower brain energy reserves may respond most strongly to supplementation. (ScienceDaily, May 2026)

How Creatine Crosses the Blood-Brain Barrier: The SLC6A8 Mechanism

One of the most clinically significant aspects of the CABA trial is the direct MRS confirmation that oral creatine crosses the blood-brain barrier in humans. The mechanism involves the SLC6A8 transporter, a sodium- and chloride-dependent creatine transporter expressed throughout the central nervous system.

Under normal physiological conditions, the brain synthesizes a portion of its creatine endogenously via the AGAT-GAMT enzymatic pathway. However, this endogenous synthesis may fall short under conditions of high metabolic demand or reduced mitochondrial efficiency, both of which become more common with age. A 2025 Frontiers in Psychiatry review documented the full role of the brain creatine system in neurological and behavioral conditions, establishing SLC6A8-mediated transport as the dominant uptake pathway for exogenous creatine in neural tissue. (Frontiers in Psychiatry, 2025)

Oral creatine supplementation raises serum creatine concentrations, increasing the concentration gradient that drives SLC6A8-mediated uptake across the blood-brain barrier. The CABA trial provides direct in vivo confirmation of this mechanism in older adults.

Supporting Evidence: The 2026 Cognition-Aging Systematic Review

The CABA trial findings align with a broader systematic review published in Nutrition Reviews (Oxford Academic) in 2026 by Marshall and colleagues. The review examined six controlled studies with a combined 1,542 participants aged 55 and older, assessing the effects of creatine supplementation on cognitive outcomes.

The review concluded that creatine supplementation was associated with positive effects on cognitive performance in older adults, with benefits observed across measures of memory, attention, and executive function. Critically, effect sizes were larger in populations with lower baseline dietary creatine intake — consistent with the hypothesis that cognitive benefits are most pronounced when the brain's creatine pool is most depleted. (Nutrition Reviews, Oxford Academic, 2026)

A 2025 Frontiers in Nutrition review on the creatine muscle-brain axis further established that 5g/day is the minimum dose reliably associated with measurable brain phosphocreatine elevation confirmed by spectroscopy — providing the mechanistic basis for maintenance-dose supplementation protocols. (Frontiers in Nutrition, 2025)

Dose-Response: What the Research Supports for Brain PCr Elevation

The CABA trial used a 20g/day loading protocol over eight weeks. For long-term supplementation, the broader research literature supports a maintenance dose of 3–5g/day as sufficient to sustain elevated tissue creatine stores after initial saturation.

Key factors influencing individual response to creatine supplementation include:

1. Baseline dietary creatine intake — Vegetarians and vegans, who consume little or no dietary creatine, show the largest increases in tissue creatine stores from supplementation, as their baseline creatine pools are significantly more depleted.
2. SLC6A8 transporter expression — Genetic variants affecting transporter density influence the rate and ceiling of brain creatine uptake.
3. Mitochondrial function — Individuals with less efficient mitochondria show larger functional responses to PCr augmentation, as the CK-PCr system contributes more of their rapid energy supply.
4. Age — Older adults demonstrate greater cognitive benefits, reflecting age-related declines in both endogenous creatine synthesis and mitochondrial efficiency.

Limitations and Open Questions

The CABA trial's sample size (n=20) is small, and the eight-week intervention period leaves long-term effects unestablished. The 20g/day loading dose exceeds typical supplementation protocols and may not be practical for continuous use outside a clinical setting.

The trial did not include a placebo arm in its primary cognitive analysis, which limits causal inference. The MRS-confirmed brain PCr elevation, however, provides an objective biomarker endpoint independent of subjective assessment.

Larger randomized controlled trials with extended follow-up and placebo controls are needed to fully characterize creatine's role in brain health as we age.

Conclusion

The 2026 CABA trial provides the strongest direct clinical evidence to date that oral creatine supplementation raises brain phosphocreatine, with emerging research linking it to better cognitive performance in older adults — putting the CK-PCr energy buffer system at the center of brain-aging research. For healthy adults, this mechanistic evidence reinforces the value of maintaining adequate daily creatine intake to support brain energy reserves before deficits accumulate.

Frequently Asked Questions

What is the CABA trial and what did it find?

The CABA trial was a 2026 clinical study from the University of Kansas Medical Center. It found that 20g/day creatine for eight weeks raised brain phosphocreatine levels by 10–15% — confirmed by MRS neuroimaging — and was associated with better scores on sorting, reading, and sustained attention assessments in older adults.

Does creatine cross the blood-brain barrier?

Yes. Creatine is transported across the blood-brain barrier via the SLC6A8 sodium- and chloride-dependent transporter. The 2026 CABA trial confirmed this in humans using magnetic resonance spectroscopy, directly measuring elevated phosphocreatine in neural tissue following oral supplementation — direct in vivo confirmation in older adults.

Is there clinical evidence that creatine supports cognition?

Emerging research says yes. A 2026 systematic review in Nutrition Reviews (Oxford Academic) examined six controlled studies across 1,542 adults aged 55+ and found creatine supplementation was associated with improved memory, attention, and executive function. The effect was largest in participants with the lowest baseline dietary creatine intake.

What is the mechanism by which creatine supports brain energy?

Creatine enables the creatine kinase–phosphocreatine (CK-PCr) system to regenerate ATP from ADP within milliseconds during periods of high neuronal demand. When energy demand outpaces supply, raising brain phosphocreatine via supplementation provides a rapid-access energy buffer independent of oxidative phosphorylation.

What dose is needed for brain phosphocreatine elevation?

Research supports 5g/day as the minimum maintenance dose reliably associated with measurable brain PCr elevation confirmed by spectroscopy. Loading protocols of 15–20g/day for 5–7 days can accelerate tissue saturation. The CABA trial used 20g/day as a sustained loading dose in a clinical setting.

Is creatine a medical therapy for memory?

No. Creatine is a dietary supplement, not a medical therapy. The CABA trial and related research suggest creatine supports brain energy, and emerging research links it to memory and focus as we age. Larger, placebo-controlled trials with longer follow-up periods are still needed.

Written by Gummy Gardens Team. Last updated June 2026.